Ensuring safety, implementation and scientific integrity of clinical trials: lessons from the Criminal Justice-Drug Abuse Treatment Studies Data and Safety Monitoring Board

被引:0
|
作者
Chandler, Redonna K. [1 ,2 ]
Dennis, Michael L. [3 ]
El-Bassel, Nabila [4 ]
Schwartz, Robert P. [5 ]
Field, Gary [6 ]
机构
[1] NIDA, Bethesda, MD 20892 USA
[2] NIDA, Serv Res Branch, Rockville, MD USA
[3] Chestnut Hlth Syst, Bloomington, IL USA
[4] Columbia Univ, Sch Social Work, New York, NY USA
[5] Friends Res Inst, Baltimore, MD USA
[6] Oregon Dept Correct, Oregon, OR USA
关键词
Clinical trial; CJ-DATS; Criminal justice; DSMB; Health services research;
D O I
10.1007/s11292-009-9076-6
中图分类号
DF [法律]; D9 [法律];
学科分类号
0301 ;
摘要
Data and safety monitoring boards (DSMBs) provide independent oversight to bio-medical clinical trials, ensuring safe and ethical treatment of research participants, data quality, and credibility of study findings. Recently, the type of research monitored by DSMBs has been expanded to include randomized clinical trials of behavioral and psychosocial interventions in community and justice based settings. This paper focuses on the development and role of a DSMB created by the National Institute on Drug Abuse (NIDA) to monitor six multi-site clinical trials conducted within the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS). We believe this is one of the first such applications of formal DSMBs in justice settings. Special attention is given to developing processes for measuring and monitoring a range of implementation issues for research conducted within criminal justice settings. Lessons learned and recommendations to enhance future DSMB work within this area are discussed.
引用
收藏
页码:323 / 344
页数:22
相关论文
共 6 条
  • [1] Ensuring safety, implementation and scientific integrity of clinical trials: lessons from the Criminal Justice–Drug Abuse Treatment Studies Data and Safety Monitoring Board
    Redonna K. Chandler
    Michael L. Dennis
    Nabila El-Bassel
    Robert P. Schwartz
    Gary Field
    [J]. Journal of Experimental Criminology, 2009, 5 : 323 - 344
  • [2] Enhancing the Scientific Integrity and Safety of Clinical Trials Recommendations for Data Monitoring Committees
    Lewis, Roger J.
    Calis, Karim A.
    DeMets, David L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (22): : 2359 - 2360
  • [3] Ensuring Patient Safety and Data Integrity in Clinical Trials for the Treatment of Bronchiolitis Obliterans Syndrome (BOS) during the COVID-19 Pandemic
    Fernandes, S. Prante
    Hagedorn, T.
    Salerio, I.
    Cuomo, D.
    Kappeler, D.
    Tutone, M.
    Witte, S.
    Vaja, V.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S316 - S316
  • [4] Data and Safety Monitoring Board activity in academic clinical trials: 6-years activity report from establishments of REVISE national group
    Duranton, S.
    Bensmail, N.
    Castera, M.
    Chiffoleau, A.
    Crepin, S.
    Deygas, B.
    Franceschi, M. P.
    Gavard, M.
    Guerin, A. L.
    Hamy, L.
    Houdas, S.
    Jamet, A.
    Kroselj, O.
    Lengelle, C.
    Muller, C.
    Nguon, M.
    Olivier, P.
    Ouk, T.
    Petitpain, N.
    Peyro-Saint-Paul, L.
    Robin, P.
    Ruault, S.
    Soichez, R.
    Touat, K.
    Toulza, E.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 67 - 67
  • [5] Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials—lessons from CULPRIT-SHOCK
    Peter Clemmensen
    Benedikt Schrage
    Uwe Zeymer
    Holger Thiele
    Karl Wegscheider
    [J]. Trials, 22
  • [6] Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials-lessons from CULPRIT-SHOCK
    Clemmensen, Peter
    Schrage, Benedikt
    Zeymer, Uwe
    Thiele, Holger
    Wegscheider, Karl
    [J]. TRIALS, 2021, 22 (01)